Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YTS104 in Relapsed or Refractory Multiple Myeloma
NCT05913804Phase 1Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jun 2023
- Primary completion
- Dec 2025
- Modality
- TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of YTS104 in multiple myeloma (MM), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: Number of Patients with Dose Limiting Toxicity at 28 days and Incidence and severity of adverse events at 24 months. Started Jun 2023; status: recruiting.
02
Drugs
YTS104
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05913804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05913804.